Aardvark Therapeutics Investors Have Opportunity to Lead Securities Fraud Lawsuit

Rosen Law Firm has announced an opportunity for investors who purchased Aardvark Therapeutics, Inc. (NASDAQ: AARD) common stock in connection with its initial public offering (IPO) on February 13, 2025, or between that date and May 14, 2026, to lead a securities fraud class action lawsuit. The deadline for investors to seek appointment as lead plaintiff is October 13, 2026.

The lawsuit alleges that Aardvark Therapeutics made materially false and misleading statements and failed to disclose adverse facts about its business, operations, and prospects. Specifically, the complaint claims that the company's drug candidate, ARD-101, was less safe than represented, leading to overstated clinical, regulatory, and commercial prospects. According to the lawsuit, these misrepresentations caused investors to suffer damages when the true details emerged.

Rosen Law Firm, which specializes in securities class actions, is encouraging investors to select qualified counsel. The firm stated that investors may be entitled to compensation without any out-of-pocket fees or costs through a contingency fee arrangement. Those who wish to serve as lead plaintiff must file with the court by the October 13 deadline.

Individuals who purchased Aardvark securities during the specified period and wish to learn more about the class action or their options can visit Rosen Law Firm's website or contact the firm directly. It is important to note that no class has yet been certified, and investors are not represented by counsel unless they retain their own.